Moneycontrol PRO
HomeAuthorViswanath pilla News

Viswanath Pilla

Senior Assistant Editor

Moneycontrol News

Biological E partners with China’s Recbio to manufacture HPV9 vaccine for India, global markets

BUSINESS

Biological E partners with China’s Recbio to manufacture HPV9 vaccine for India, global markets

Under the terms of the deal, Recbio will transfer the technology and supply the drug substance (DS) to BE, enabling the Indian firm to formulate, fill, and package the vaccine.

Torrent Pharma to become India’s fifth-largest drugmaker after JB Pharma acquisition

BUSINESS

Torrent Pharma to become India’s fifth-largest drugmaker after JB Pharma acquisition

The acquisition and subsequent merger will create a pharmaceutical powerhouse with combined revenues exceeding Rs 15,000 crore and EBITDA of over Rs 4,800 crore, based on FY25 pro forma figures.

Torrent Pharma revives talks to acquire KKR’s stake in JB Pharma; deal expected soon

BUSINESS

Torrent Pharma revives talks to acquire KKR’s stake in JB Pharma; deal expected soon

KKR’s stake is worth approximately Rs 13,400 crore considering the J B Pharma stock’s closing price of Rs 1,802.9 per share on June 27.

Vertex Pharma's stem cell therapy may have potential to cure type-1 diabetes, shows clinical trial

BUSINESS

Vertex Pharma's stem cell therapy may have potential to cure type-1 diabetes, shows clinical trial

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete insulin independence within one year of treatment.

AstraZeneca pumps in Rs 166 crore into Global Hub in Bengaluru, will add 400 new jobs

BUSINESS

AstraZeneca pumps in Rs 166 crore into Global Hub in Bengaluru, will add 400 new jobs

The new facility will house nearly 1300 employees, including 400 new jobs, supporting the company's capabilities in AI-powered innovation across Research and Development, Global Business Services, IT, and Digital Health operations.

French drugmaker Servier targets India expansion with cancer therapies, R&D

BUSINESS

French drugmaker Servier targets India expansion with cancer therapies, R&D

The company is also looking to broaden generics portfolio, explore clinical trials and examine the possibility of a global capability centre, Servier India MD Aurélien Breton tells Moneycontrol

CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format

BUSINESS

CDSCO allows Lilly to launch weight-loss drug Mounjaro in pen format

The KwikPen is a multi-dose, single-patient-use prefilled pen designed for once-in-a week administration

Bharat Biotech, GSK to halve malaria vaccine price to less than $5 per dose

BUSINESS

Bharat Biotech, GSK to halve malaria vaccine price to less than $5 per dose

Bharat Biotech has entered into partnership in 2021 to produce part of the malaria vaccine that has been developed by British drugmaker GSK, the company has invested $200 million in building manufacturing capacities for the vaccine.

Air India employees looking at leadership to guide them at a time of despair

BUSINESS

Air India employees looking at leadership to guide them at a time of despair

Multiple pilots and cabin crew Moneycontrol spoke to also indicated that while there is a heightened sense of compassion and concern being expressed by senior leaders with regard to the work load and mental well-being of employees following the June 12 crash, many have questioned the sincerity, delayed recognition and extent of the compassion being displayed by senior leadership.

Novo Nordisk follows smart pricing for Wegovy in India; easy to use, says top local executive

BUSINESS

Novo Nordisk follows smart pricing for Wegovy in India; easy to use, says top local executive

'We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, Managing Director of Novo Nordisk India, in an interview with Moneycontrol.

Novo Nordisk launches blockbuster weight loss drug Wegovy in India

TRENDS

Novo Nordisk launches blockbuster weight loss drug Wegovy in India

The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.

Indira IVF acquires Ahmedabad-based Banker IVF to expand fertility care services

BUSINESS

Indira IVF acquires Ahmedabad-based Banker IVF to expand fertility care services

The collaboration will increase Indira IVF's presence in Gujarat, adding to its existing centers in Ahmedabad, Vadodara, Rajkot, Mehsana, and other key locations, the company said.

Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal

BUSINESS

Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal

Biocon’s debt profile has been under investor scrutiny after a strategic acquisition of Viatris Inc's biosimilars business for roughly $3.3 billion in 2022. This deal, while transformative for Biocon Biologics, had significantly increased the company's leverage.

What does Gilead’s twice-a-year shot means for fight against HIV? When will India get Yeztugo?

BUSINESS

What does Gilead’s twice-a-year shot means for fight against HIV? When will India get Yeztugo?

The US FDA on June 18 gave its nod to Yeztugo, which can prove to be turning point in the battle against HIV but its high price and access remains a concern

How a Mumbai startup stepped up during Covid to disrupt the global biopharma supply chain

BUSINESS

How a Mumbai startup stepped up during Covid to disrupt the global biopharma supply chain

Founded in 2017 by industry veterans Ankush Kapoor and Sachin Joshi, PharmNXT pivoted from being a distributor of European bioprocessing technologies to becoming a full-fledged manufacturer—building India’s first domestic supply chain for single-use biopharma systems.

Abbott to distribute MSD's diabetes drug and its combinations in India

BUSINESS

Abbott to distribute MSD's diabetes drug and its combinations in India

The drug patents expired in India in July 2022, which has triggered a wave of generic launches and steep price corrections across the market.

Indian pharma companies sit on record cash pile, set sights on acquisitions

BUSINESS

Indian pharma companies sit on record cash pile, set sights on acquisitions

In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers

Quadria Group launches $300 million HealthQuad Fund III to build India’s largest healthcare investment platform

BUSINESS

Quadria Group launches $300 million HealthQuad Fund III to build India’s largest healthcare investment platform

HealthQuad Fund III will focus on early to late-stage investments across India’s healthcare value chain, targeting tech-enabled models in diagnostics, chronic care, and digital health.

Indian drugmakers gearing up to target global weight-loss market as semaglutide patents begin to expire in 2026

BUSINESS

Indian drugmakers gearing up to target global weight-loss market as semaglutide patents begin to expire in 2026

Industry executives say the opportunity is “massive,” with demand expected to surge as prices fall.

Serum Institute, DNDi in pact to develop affordable dengue antibody therapy for lower-income nations

BUSINESS

Serum Institute, DNDi in pact to develop affordable dengue antibody therapy for lower-income nations

The collaboration will focus on advancing the potential drug candidate—formerly known as VIS513—through Phase III clinical trials in India, Brazil and other dengue-endemic countries.

Even Healthcare bets big on hospital expansion, targets 25 facilities in 36 months

BUSINESS

Even Healthcare bets big on hospital expansion, targets 25 facilities in 36 months

The hospitals will not offer tertiary services such as oncology or cardiac care, allowing for a leaner capex model with an average investment of $3.5 million per hospital, Even Healthcare co-founder and COO Matilde Giglio tells Moneycontrol, as the company pivots from digital-first care to full-stack healthcare delivery

OneSource gears up for launch of generic anti-diabetes, obesity drugs, looks to double revenue in 3 years

BUSINESS

OneSource gears up for launch of generic anti-diabetes, obesity drugs, looks to double revenue in 3 years

The patent for semaglutide, the active ingredient in blockbuster Ozempic and Wegovy, expires in more than 100 countries, including India, in 2026. The generic semaglutide launch will redefine OneSource's growth trajectory, CEO Neeraj Sharma tells Moneycontrol

Renalyx unveils indigenously built low cost dialysis machine

BUSINESS

Renalyx unveils indigenously built low cost dialysis machine

The dialysis machine called RENALYX – RxT 21 with a starting price of ₹6.70 lakh, with an aim to reduce the total cost of ownership by 40% compared to imported alternatives.

Eli Lilly 'encouraged' by response to weight-loss drug Mounjaro in India, maps expansion

BUSINESS

Eli Lilly 'encouraged' by response to weight-loss drug Mounjaro in India, maps expansion

Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India, says the drugmaker is tying up with healthcare players to spread awareness about the dual epidemic of obesity and diabetes

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347